Achillion Pharmaceuticals Inc (NASDAQ:ACHN) EVP Joseph Truitt sold 50,000 shares of Achillion Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $6.02, for a total value of $301,000.00. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) weekly performance is 169.04%. On last trading day company shares ended up $7.29. Analysts mean target price for the company is $5.44. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) distance from 50-day simple moving average (SMA50) is 144.65%.
Sangamo Biosciences Inc (NASDAQ:SGMO) SVP Philip D. Gregory sold 15,000 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $12.85, for a total value of $192,750.00. Following the completion of the sale, the senior vice president now directly owns 109,347 shares in the company, valued at approximately $1,405,109. Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares fell -1.66% in last trading session and ended the day on $ 16.00. Its return on assets is -17.90%. Sangamo Biosciences, Inc. (NASDAQ:SGMO) quarterly performance is -31.30%.
Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Cozadd sold 5,000 shares of the company’s stock on the open market in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $142.34, for a total transaction of $711,700.00. Following the completion of the sale, the chief executive officer now directly owns 602,067 shares of the company’s stock, valued at approximately $85,698,217. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares moved up 1.31% in last trading session and was closed at $143.23, while trading in range of $139.96 – $143.52. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) year to date (YTD) performance is 13.17%.
Ophthotech Corp (NASDAQ:OPHT) major shareholder Lifesciences Ii L.P. Clarus sold 211,680 shares of the company’s stock on the open market in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $45.42, for a total value of $9,614,505.60. Ophthotech Corp (NASDAQ:OPHT) ended the last trading day at $44.50. Company weekly volatility is calculated as 5.15% and price to cash ratio as 5.56. Ophthotech Corp (NASDAQ:OPHT) showed a positive weekly performance of 1.22%.
Acceleron Pharma Inc (NASDAQ:XLRN) CEO John L. Knopf sold 15,000 shares of Acceleron Pharma stock on the open market in a transaction dated Monday, June 9th. The shares were sold at an average price of $31.65, for a total value of $474,750.00. Following the completion of the sale, the chief executive officer now directly owns 191,500 shares of the company’s stock, valued at approximately $6,060,975.Acceleron Pharma Inc (NASDAQ:XLRN) weekly performance is 9.05%. On last trading day company shares ended up $33.06. Analysts mean target price for the company is $55.00. Acceleron Pharma Inc (NASDAQ:XLRN) distance from 50-day simple moving average (SMA50) is -1.88%.
Leave a Reply